Literature DB >> 6401219

Role of N-methylolpentamethylmelamine in the metabolic activation of hexamethylmelamine.

M M Ames, M E Sanders, W S Tiede.   

Abstract

Hexamethylmelamine (HMM) is metabolized by rat hepatic microsomal preparations to reactive species which covalently bind to microsomal protein and to calf thymus DNA added to microsomal incubation mixtures. Covalent binding to macromolecules is dependent on the presence of molecular oxygen and reduced nicotinamide adenine dinucleotide phosphate and is catalyzed by cytochrome P-450 monooxygenases. Reduced nicotinamide adenine dinucleotide-dependent covalent binding of [methyl-14C]HMM to microsomal protein is greater than that of [ring-14C]HMM. Reduced nicotinamide adenine dinucleotide phosphate-dependent covalent binding of [ring-14C]HMM and [methyl-14C]HMM to calf thymus DNA added to microsomal incubation mixtures are approximately equal. The [ring-14C]-labeled carbinolamine intermediate in HMM demethylation, N-methylolpentamethylmelamine, covalently binds to microsomal protein and, to a much greater extent, to calf thymus DNA.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6401219

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Pharmacokinetics and metabolism of hexamethylmelamine in mice after IP administration.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes.

Authors:  Nan Zheng; Peng Zou; Shaomeng Wang; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2010-12-22       Impact factor: 3.922

Review 3.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Pharmacokinetics and metabolism of hexamethylmelamine in mice bearing renal cell tumors.

Authors:  J Dubois; G Atassi; M Hanocq; F Abikhalil
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Effect of a hepatic activation system on the antiproliferative activity of hexamethylmelamine against human tumor cell lines.

Authors:  K J Miller; R M McGovern; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of altretamine.

Authors:  G Damia; M D'Incalci
Journal:  Clin Pharmacokinet       Date:  1995-06       Impact factor: 6.447

7.  In vivo antitumor activity of hexamethylmelamine against human breast, stomach and colon carcinoma xenografts.

Authors:  H Tanino; T Kubota; Y Yamada; J Koh; S Kase; T Furukawa; T H Kuo; Y Saikawa; M Kitajima; Y Naito
Journal:  Jpn J Cancer Res       Date:  1995-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.